Kirk Cousins’ future hangs in the balance. Whilst rumors have floated around about his future, surrounding potential trades, ...

周四，Truist Securities重申了对Viking Therapeutics (NASDAQ:VKTX)股票的买入评级和120.00美元的目标价。这一积极立场源于竞争对手数据未达预期，增强了对Viking的VK2735治疗的信心。

圣地亚哥 - Viking Therapeutics, Inc. (NASDAQ: VKTX)过去一年股价上涨了令人印象深刻的114%，该公司已经启动了VK2735的二期临床试验，这是一种旨在治疗肥胖症和相关代谢疾病的口服药物。根据 InvestingPro ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it ...

Archaeologists recently unveiled remarkable treasure from an excavation at the Skumsnes farm in Fitjar last autumn, including ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...